Vol. XXX, n.2, 2009 ISSN: 0392-2936


european journal
of gynaecological oncology

an International Journal


Founding Editor
A. Onnis
Montréal (Canada)

Editors-in-Chief
M. Marchetti
Montréal (Canada)
P. Bösze
Budapest (Hungary)

Associate Editor
T. Maggino
Padua (Italy)

Assistant Editor
J. Wilson
San Diego - CA (USA)
Editorial Board
Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Ba˘nceanu G., Bucarest (Romania)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,
Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Friedrich M., Hamburg (Germany)
Fuller A.F. Jr., Boston, MA (USA)
Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M.,
Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,
Athens (Greece)
Jordan J.A.,
Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G.,
Nijmegen (The Netherlands)
Menczer J., Savyon (Israel)
Monsonego J., Paris (France)
Pálfalvi L., Budapest, (Hungary)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H.,
London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan)

Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com - www.irog.net

Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

 

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

 

European Journal of Gynaecological Oncology
www.irog.net


General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distin-guished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the dif-fusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted 6 months before publication and will be published free of charge.
BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.
ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate infor-mation, the publisher accepts no responsibility for the consequences of faultful or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.


SUBSCRIPTION INFORMATION
The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is $390 US for Institutions, $200 US for Individuals. For airmail add $30, for receipt add $10 US. Single copy prepaid cost $95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only US Funds are accepted. No bank transfers.

Claims for missing issues can be honoured up to six months. Changes of address: allow six weeks for all changes to become effec-tive. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and any communication and requests should be addressed to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT

 

European Journal of Gynaecological Oncology
www.irog.net


Instructions to Authors

SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the “Distinguished Expert Series” should be submitted to P. Bösze, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers’ suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publi-cation cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author’s experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and appli-cation thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS
The Journal follows the “Uniform requirements for manuscripts submitted to biomedical journals” published in the New England Journal of Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.

Three manuscripts, typed and double spaced should be submitted with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0. Manuscripts without an electronic disk will not be accepted. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been pub lished or submitted for publication elsewhere. Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the Corresponding Author, responsible for revision and approval of the proofs, should be indicated. Full-length articles should not exceed 8 printed pages including tables and references.

After the title page (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: Summary (purpose of investiga-tion, methods, results, conclusion - about 150 words), Key words, Content (a 20-word summary), Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement (if any), References, Tables, Legends.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author’s name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors’ surname and initials (if more than six names, give six followed by “et al.”), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors’ surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments
will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline the proofs will be considered approved. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS
The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. Only payments in US dollars will be accepted. No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.



© By I.R.O.G. CANADA INC. - Publisher - Editorial office 4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3 (Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy) - Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s Court n. 633 - 28-6-1979
   
European Journal of Gynaecological Oncology - Vol. XXX, n.2, 2009
 
   
CONTENTS  
DISTINGUISHED EXPERT SERIES  
History of the International Federation of Cervical Pathology and Colposcopy (IFCPC)* 117
G.R. di Paola - Buenos Aires, ARGENTINA
A lecture on the history of the International Federation of Cervical Pathology and Colposcopy.
 
 
REVIEW ARTICLE  
New cytokine: stromal derived factor-1 124
K. Jaszczyñska-Nowinka, A. Markowska - Poznan, POLAND
The SDF-1+CXCR4 complex plays a significant role in the creation of metastases of neoplasms and as a response to cytostatic treatment.
 
Human papilloma virus molecular profile and mechanisms of cancerogenesis: a review 128
E. Deligeoroglou, P. Christopoulos, L. Aravantinos, K. Papadias - Athens, GREECE
Basic and advanced knowledge on HPV molecular biology and the mechanisms of cancerogenesis.
 
 
ORIGINAL ARTICLES  
Expression of secreted frizzled-related protein 4 (SFRP4) in primary serous ovarian tumours 133
J. Drake, A.M. Shearwood, J. White, R. Friis, N. Zeps, A. Charles, A. Dharmarajan - Western Australia, AUSTRALIA
SFRP4 and B-catenin expression in ovarian serous carcinoma using immunohistochemistry were inversely related but did not affect survival.
 
Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma 142
F. Zucchi, I.D.C.G. da Silva, J.C.L. Ribalta, N.C.N. de Souza, N.M. de Góis Speck, M.J.B.C. Girão, S.M.F. Brenna, K.J. Syrjänen - São Paulo, BRAZIL
The FAS/CD95 promoter polymorphism gene is associated with an increased risk of cervical cancer in women under 48 years of age.
 
Trends of histopathology of cervical cancer among women in Durban, South Africa 145
M. Moodley, K. Moodley - Durban, SOUTH AFRICA
No statistically significant relationship was identified between the presence of HPV recorded in the histopathology report and the different histological types of cervical cancer.
 
Chest computed tomography before evacuation of hydatidiform mole 151
D.G. Hong,Y.L. Cho, Il S. Park,Y.S. Lee - Daegu, KOREA
The usefulness of chest CT in the initial evaluation of hydatidiform mole was studied.
 
Clinical outcome and prognostic factors in borderline tumors of the ovary. Results from 17 years’ experience in the Kinki District of Japan (1990-2006) 155

K. Kokawa,Y. Mikami, H. Sakata, N. Oki, T. Tanaka, M. Yamazaki, Y. Nakata, N. Umesaki - Kyoto, JAPAN
The prognosis of patients with borderline ovarian tumors is excellent.

 
Microsatellite instability and HPV genotype in Polish women with cervical cancer 162
M.F.D. Baay, M. Nakonieczny, I. Wozniak, V. Deschoolmeester, J. Liss, K. Lukaszuk, K. Sotlar, J. Emerich, J.B. Vermorken - Tübingen, GERMANY
Microsatellite instability was detected in 12.6% of cervical carcinoma patients, but no correlation with clinicopathological parameters or survival was found.
 
Accuracy of preoperative magnetic resonance imaging in assessing lymph node metastasis and myometrial invasion in patients with uterine cancer 167
S.C. Yoo,W.Y. Kim, J.H. Yoon, H.Y. Kim, E.J. Lee, S.J. Chang, K.H. Chang, H.S. Ryu - Suwon, KOREA
Preoperative evaluation of uterine cancer by MRI does not accurately predict lymph node metastasis and deep myometrial invasion.
 
Total laparoscopic hysterectomy in morbidly obese women with endometrial cancer anaesthetic and surgical complications 171
T. O’Gorman, N. MacDonald, T. Mould, A. Cutner, R. Hurley, A. Olaitan - London, UK
Surgical and anaesthetic morbidity in morbidly obese women treated by total laparoscopic hysterectomy and bilateral salpingooophorectomy for endometrial cancer.
 
Metastatic involvement of the urinary tract in patients with advanced ovarian carcinoma: lessons from the autopsy for an interdisciplinary treatment approach 174
S. Wyler, D.J. Huang, G. Singer, A. Schötzau, W. Holzgreve, U. Güth - Basel, SWITZERLAND
Frequency and extent of metastases in urologic organs found at autopsy of ovarian carcinoma patients were evaluated, and the consequences of these findings for the clinical management of these patients are demonstrated.
 
Risk of malignancy index for adnexal masses 178
N. Akdeniz, U. Kuyumcuog˘lu, A. Kale, M. Erdemog˘lu, F. Caca - Diyarbakir, TURKEY
The effectiveness of the RMI (risk of the malignancy index) algorithm in patients with adnexal masses is reported.
 
Genetic imbalance related to cisplatin-based chemoresistance in epithelial ovarian cancer 181
Y. Huanchun, Z. Shulan, L. Jing - Shenyang, PR OF CHINA
Non-random chromosome gains and losses with cisplatin-resistant epithelial ovarian cancer was documented. Genes in these regions were related to a drug-resistant phenotype.
 
Women’s lifestyle and the risk of breast tumors 186
B. Pie˛ta, D. Samulak, T. Opala, G. Iwanowicz-Palus, M. Wilczak, S. Grodecka-Gazdecka, K. Wie˛znowska-Maczynska - Kalisz, POLAND
The study was focused on analysis of the potential influence of women’s lifestyle on the risk of developing breast tumors.
 
Radicality of surgical treatment for cervical cancer 190
L. Mirkovic´, S. Petkovic´, D. Mirkovic´, K. Jeremic´, V. Milenkovic´, M. Maksimovic´ - Belgrade, SERBIA
A study of 545 Wertheim-Meigs radical hysterectomies over a four-year period was carried out.
 
 
CASE REPORTS  
Recurrent cervical cancer presenting as malignant pericarditis: Case report and review of the literature 193
L. Verleye, N. Thomakos, R.J. Edmondson - Athens, GREECE
Metastatic pericardial effusion in cervical cancer patients is extremely rare. Symptomatic relief and treatment of the underlying disease may improve survival and quality of life.
 
Biopsy-proven cerebellar metastasis from a malignant mixed mullerian tumor (MMMT) of the uterus: case report 196
J.K. Kim, S.K. Lee, N.H. Myong,Y.D. Kang - Cheonan, KOREA
A rare case of cerebellar metastasis from MMMT of the uterus diagnosed by biopsy is presented.
 
Metastatic leiomyosarcoma diagnosed after uterine artery embolization 199
H.E. Stohl Posy, J.C. Elkas, A.V. Yemelyanova, T.P. Diaz-Montes, R.E. Bristow, R.L. Giuntoli II - Baltimore, MD (USA)
A case of leiomyosarcoma involving a substernal mass diagnosed in a premenopausal woman with an antecedent history of uterine artery embolization is presented.
 
Management of myoepithelioma of the vulva - case report and review of the literature 203
C. Georgantopoulou, I. Aird - Athens, GREECE
The prognosis in myoepithelioma of the vulva depends on histology and its management should be based on the histological grade.
 
Conservative management of uterine leiomyosarcoma: report of a failure 206
G. Cormio, V. Loizzi, C. Carriero, D. Scardigno, G. Putignano, L. Selvaggi - Bari, ITALY
Conservative management of a young patient with leiomyosarcoma was performed, however the patient died of disease 48 months after primary diagnosis.
 
Two cases of ovarian cancer at an early stage incidentally detected using transvaginal ultrasonography in screening: Importance of interval for ovarian cancer screening and selection of population with a high risk of ovarian cancer 208
A. Fukuyama,Y. Yokoyama, J. Wada, T. Hashimoto, T. Oda, S. Sato, H. Mizunuma - Mutsu, JAPAN
An appropriate interval of ovarian cancer screening according to risk factors of ovarian cancer is reported.
 
Villoglandular papillary adenocarcinoma of the uterine cervix: a case report and literature review 211
E. González Bosquet, M. Suñol, D. Morante, M. Gomez Latre, J. Callejo, J.M. Lailla - Barcelona, SPAIN
Villoglandular papillary adenocarcinoma is a form of cervical adenocarcinoma with a good prognosis. A case study and literature review are presented.
 
Obstructive uropathy secondary to parametrial metastasis: an unusual presentation of breast carcinoma 214
R.R. Nair, M.D. Conroy, A.R. Jeyarajah - London, UK
An unusual presentation of occult breast carcinoma with parametrial metastasis is discussed.
 
A case of HMB45-negative perivascular epithelial cell tumor (PEComa) of the uterine corpus: A possible diagnostic application of molecular-cytogenetic analysis 216
Y. Yamagata, S. Kawauchi, H. Tamura, A. Murakami, K. Sasaki, N. Sugino - Ube, JAPAN
A case of uterine PEComa in a 25-year-old woman with X trisomy revealed by FISH is reported.
 
Vascular tumors: rare neoplasms of the female genital tract 220
A. Liapis, K. Bakalianou, N. Salakos, C. Iavazzo, I. Dalainas, A. Kondi-Pafiti - Athens, GREECE
A retrospective study of the clinicopathological findings of vascular tumors of the female genital tract is reported.
 
Primary carcinoid tumor arising in a mature cystic teratoma of the ovary: A case report 223
N. Guney, T. Sayilgan, D. Derin, D. Özcan - Kayseri, TURKEY
A case of primary carcinoma developing from a mature teratoma of the ovary is described.
 
Ovarian dermoid cyst with malignant transformation and rupture of the capsule associated with chemical peritonitis: a case report and literature review 226
B.B. da Silva, A.R. dos Santos, P.V. Lopes-Costa, E.C. Sousa-Jr., M.V. Correa-Lima, C.G. Pires - Piauí, BRAZIL
Malignant transformation of ovarian dermoid cysts is rare and the spontaneous rupture provoking chemical peritonitis is even rarer.
 
A unique case of palatinate tonsil metastasis from endometrial cancer 229
L. Zepiridis, M. Zafrakas, T.D. Theodoridis, K. Kaplanis, K.K. Dinas, J.N. Bontis - Thessaloniki, GREECE
The first case of endometrial adenocarcinoma, and female genital tract tumour in general, metastasizing to the palatinate tonsil is presented.
 
Bilateral ovarian Burkitt’s lymphoma 231
L. Gutiérrez-García, N. Medina Ramos, R. García Rodríguez, M.A. Barber, M.D. Arias, J.Á. García - Las Palmas de Gran Canaria, SPAIN
A case of Burkitt’s lymphoma in a 34-year-old patient from Senegal is reported.
 
Malignant adenomyoepithelioma of the breast - case report 234
A. Zizi-Sermpetzoglou, Th. Vasilakaki, X. Grammatoglou, N. Petrakopoulou, M.E. Nikolaidou, C. Glava - Piraeus, GREECE
A case of an 80-year-old woman with malignant adenomyoepithelioma of the breast is presented.
 
Synchronous primary tumors: appendiceal and ovarian cancer - case report 237
T. Bozˇanovic´, A. Ljubic´, P. Momcˇilov, T. Mostic´, L. Vojvodic´, S. Vidakovic´ - Belgrade, SERBIA
A case of a 64-year-old patient treated for synchronous primary tumors of appendiceal and ovarian origin is presented.
 
A rare case of renal cell carcinoma metastasizing to the uterine cervix 239
M. Zafraks, A.N. Papanikolaou, I.D. Venizelos, D. Kellartzis, T. Agorastos, J.N. Bontis - Thessaloniki, GREECE
A rare case of renal cell carcinoma metastasizing to the uterine cervix is presented.
 
Book Review 241